Market Closed -
OTC Markets
10:26:06 2024-04-19 am EDT
5-day change
1st Jan Change
0.01
USD
+257.14%
0.00%
+9,900.00%
Acura Pharmaceuticals : New Financial Obligation - Form 8-K
December 06, 2023 at 02:38 pm EST
Amended Loan Schedule to Secured Promissory Note dated November 10, 2022
between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC
Date
Principal
Aggregated Principal
Original Secured Promissory Note
11/10/2022
$2,319,279
$2,319,279
Additional loans to be included:
Loan #1
12/22/2022
$250,000
$2,569,279
Loan #2
1/19/2023
$250,000
$2,819,279
Loan #3
2/22/2023
$250,000
$3,069,279
Loan #4
3/20/2023
$250,000
$3,319,279
Loan #5
5/19/2023
$150,000
$3,469,279
Loan #6
7/10/2023
$200,000
$3,669,279
Loan #7
7/28/2023
$250,000
$3,919,279
Loan #8
8/30/2023
$250,000
$4,169,279
Loan #9
10/11/2023
$250,000
$4,419,279
Loan #10
12/04/2023
$250,000
$4,669,279
ACURA PHARMACEUTICALS, INC.
By: /s/ Peter A. Clemens
Peter A. Clemens
Senior Vice President & Chief Financial Officer
Date: December 4, 2023
Disclaimer
Acura Pharmaceuticals Inc. published this content on 06 December 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 06 December 2023 19:37:20 UTC .
Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC
Mar. 26
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC
Mar. 13
CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC
Feb. 14
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding
Feb. 13
CI
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note
Dec. 21
CI
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors
23-09-25
CI
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets
23-08-31
CI
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03
23-08-30
CI
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement
23-08-16
CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC
23-07-28
CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
23-06-30
CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
23-06-30
CI
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
23-06-29
CI
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC
23-06-28
CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from Abuse Deterrent Pharma, LLC
23-05-26
CI
Acura Pharmaceuticals, Inc. Provides Development Update on LTX-03
23-02-13
CI
Acura Pharmaceuticals, Inc. Announces First Clinical Study for Its Investigational Drug LTX-03
23-02-02
CI
Acura Pharmaceuticals, Inc. announced that it has received $2.319279 million in funding from Abuse Deterrent Pharma, LLC
22-11-09
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding
22-10-12
CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from John Schutte
22-08-26
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding
22-08-22
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.15 million in funding
22-07-17
CI
Acura Pharmaceuticals, Inc Enters into License, Development and Commercialization Agreement with Abuse Deterrent Pharmaceuticals LLC
22-07-14
CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from John Schutte
22-07-11
CI
Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding
22-05-19
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
More about the company
1st Jan change
Capi.
+9,900.00% 663K -2.31% 103B +0.56% 95.28B +1.69% 22.15B -17.37% 21.02B -9.30% 18.15B -41.01% 16.74B -14.85% 16.05B +3.21% 13.68B +33.54% 12.17B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
ACURA PHARMACEUTICALS, INC. 
